Fed. Circ. Knocks Down $1.7B Humira Patent Verdict
The U.S. Court of Appeals for the Federal Circuit found that the key claims of Centocor Ortho Biotech Inc.'s patent were invalid for lack of written description.
The court concluded the jury in the U.S. District Court for the Eastern District of Texas lacked substantial evidence for its June 2009 verdict, the largest of...
To view the full article, register now.